Production (Stage)
Cidara Therapeutics, Inc.
CDTX
$24.28
-$1.42-5.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -- | -94.07% | -84.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -- | -94.07% | -84.36% |
| Cost of Revenue | 98.24% | 485.19% | 19.67% | -23.10% | -97.66% |
| Gross Profit | -160.32% | -792.16% | -963.22% | -78.16% | 121.38% |
| SG&A Expenses | 71.83% | 112.01% | 50.50% | 49.20% | -1.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 165.57% | 372.92% | 27.10% | -3.67% | -28.80% |
| Operating Income | -195.82% | -522.71% | -289.30% | -64.51% | -19.59% |
| Income Before Tax | -187.15% | -540.68% | -302.98% | -1,438.12% | -18.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -187.15% | -540.13% | -306.36% | -1,428.14% | -18.32% |
| Earnings from Discontinued Operations | -- | -98.75% | 91.48% | 140.23% | -121.65% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -127.39% | -1,527.98% | -75.52% | -569.47% | -442.71% |
| EBIT | -195.82% | -522.71% | -289.30% | -64.51% | -19.59% |
| EBITDA | -196.65% | -524.62% | -290.31% | -64.57% | -19.62% |
| EPS Basic | 27.22% | -657.34% | -21.35% | -560.98% | -397.19% |
| Normalized Basic EPS | 8.09% | -198.05% | -178.60% | -50.34% | -2.61% |
| EPS Diluted | 27.22% | -655.13% | -21.20% | -560.82% | -397.19% |
| Normalized Diluted EPS | 8.09% | -198.05% | -178.60% | -50.34% | -2.61% |
| Average Basic Shares Outstanding | 212.44% | 114.97% | 44.65% | 1.29% | 15.31% |
| Average Diluted Shares Outstanding | 212.44% | 114.97% | 44.65% | 1.29% | 15.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |